Terms ending in 2034
Every in-force patent on Seegene, Inc.'s record whose computed term ends in 2034, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 10,106,841 | Quantification of Target Nucleic Acid Using Common Internal Control In force · High confidence | Seegene, Inc. | In force | High confidence | |
| US 9,840,739 | Method for Determining SNP Genotype In force · High confidence | Seegene, Inc. | In force | High confidence | |
| US 11,702,699 | Detection of Nucleotide Variation on Target Nucleic Acid Sequence In force · High confidence | Seegene, Inc. | In force | High confidence | |
| US 10,752,938 | Detection of a Target Nucleic Acid Sequence Using Two Different Detection Temperatures In force · Medium confidence | Seegene, Inc. | In force | Medium confidence | |
| US 12,291,740 | Detection of Target Nucleic Acid Sequences Using Different Detection Temperatures In force · Medium confidence | Seegene, Inc. | In force | Medium confidence | |
| US 10,106,840 | Quantification of Target Nucleic Acid Using Melting Peak Analysis In force · High confidence | Seegene, Inc. | In force | High confidence |
6 of 6 patents shown. Soonest term end first, then patent number.
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.